★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
AbbVie Inc. (ABBV) Moat Analysis
AbbVie Inc.
ABBV · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
AbbVie is a U.S. biopharmaceutical company concentrated in Immunology and diversified across Neuroscience, Oncology, Aesthetics, Eye Care and other specialty products. Its clearest moat is asset-specific: Rinvoq settlement licenses delay expected U.S. generic entry to April 2037 if pediatric exclusivity applies, and Skyrizi plus Rinvoq generated $14.632B in H1 2026. Humira's 37.2% decline after biosimilar entry demonstrates that this protection is valuable but finite. The only other retained moat is the Botox-led Aesthetics brand position; portfolio-wide patent and therapeutic-brand claims in Oncology and Neuroscience were removed because the cited evidence did not establish a durable segment advantage. The SEC filing confirms ordinary shares trade on both NYSE and NYSE Texas; there is no ADR layer.
Primary segment
Immunology
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
6 segments · 10 tags
Updated 2026-08-23
Segments
Immunology
Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)
Revenue
48.9%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Oncology
Oncology therapeutics (hematologic malignancies and solid tumors; targeted therapies, combinations, and ADCs)
Revenue
10.9%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Neuroscience
Neuroscience therapies (migraine, psychiatry, movement disorders; includes therapeutic neurotoxin)
Revenue
17.5%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Aesthetics
Medical aesthetics (aesthetic neurotoxins, dermal fillers, and related clinic-sold products)
Revenue
7.9%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
Eye Care
Ophthalmology pharmaceuticals (glaucoma, retina/implant therapies, dry eye and other eye care)
Revenue
3.4%
Structure
Competitive
Pricing
weak
Share
—
Peers
Other Key Products
Other specialty/legacy pharmaceuticals (e.g., HCV antivirals, gastrointestinal, metabolic and other categories)
Revenue
11.4%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
Immunology
Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)
Revenue_share uses the latest fully granular annual product table: Immunology generated $29.894B of AbbVie's $61.160B FY2025 net revenue. The H1 2026 10-Q reports $16.076B for Skyrizi, Rinvoq and Humira combined, or 50.25% of $31.992B total net revenue.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
This is an asset-specific moat, not a generic pharmaceutical-regulation claim. AbbVie identifies Skyrizi and Rinvoq composition-of-matter patents through 2033, and settlement licenses delay expected U.S. Rinvoq generic entry until April 2037 if pediatric exclusivity applies. H1 2026 revenue growth and Humira erosion after loss of exclusivity show both the current value and the finite duration of that protection.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity and biosimilar/generic entry (rapid net price and volume erosion)
- Patent challenges, adverse litigation outcomes, or settlements on less favorable terms
- Payer/formulary pressure and step-edits reducing realized net pricing
Leading indicators
- Skyrizi and Rinvoq net revenue growth vs prior year
- Share trends in psoriasis/IBD/RA and other labeled indications
- Formulary positioning and rebate pressure in U.S. channels
Counterarguments
- Therapeutic areas are crowded; clinical differentiation can narrow as competitors launch new agents
- Large payers can force switches or limit access, blunting pricing leverage despite IP
Oncology
Oncology therapeutics (hematologic malignancies and solid tumors; targeted therapies, combinations, and ADCs)
Revenue_share uses the latest fully granular annual product table: Oncology generated $6.655B of AbbVie's $61.160B FY2025 net revenue. H1 2026 oncology revenue was $3.281B: Venclexta and newer assets grew, but Imbruvica fell 27.1%. The prior portfolio-wide IP claim was removed because no cited asset-specific duration established a durable segment advantage beyond ordinary time-limited drug protection.
Neuroscience
Neuroscience therapies (migraine, psychiatry, movement disorders; includes therapeutic neurotoxin)
Revenue_share uses the latest fully granular annual product table: Neuroscience generated $10.699B of AbbVie's $61.160B FY2025 net revenue. H1 2026 neuroscience revenue was $6.103B and every named growth brand expanded, but broad approval, prescriber familiarity and generic patent reliance do not independently prove durable brand trust or an asset-specific segment moat.
Aesthetics
Medical aesthetics (aesthetic neurotoxins, dermal fillers, and related clinic-sold products)
Revenue_share uses the latest fully granular annual product table: Aesthetics generated $4.860B of AbbVie's $61.160B FY2025 net revenue. H1 2026 revenue was $2.468B; Botox Cosmetic grew 11.9% as reported while Juvederm and Other Aesthetics declined.
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Botox Cosmetic and Juvederm are long-standing brands with broad provider adoption and consumer awareness; AbbVie positions the portfolio as holding leading market positions across major aesthetics markets.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Consumer demand declines in recessions / discretionary spending weakness
- Competition from alternative toxins/fillers and aggressive provider discounting
- Reputational damage from safety issues or social/media backlash
Leading indicators
- Botox Cosmetic and Juvederm revenue trends and pricing/mix commentary
- Provider inventory levels and destocking/restocking cycles
- Competitive launch cadence and pricing/promotional intensity
Counterarguments
- Aesthetics switching costs can be low for price-sensitive consumers and providers
- New entrants can gain share via discounting, influencer marketing, or comparable outcomes
Eye Care
Ophthalmology pharmaceuticals (glaucoma, retina/implant therapies, dry eye and other eye care)
Revenue_share is derived from AbbVie FY2025 worldwide net revenues by product table: Eye Care products (Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, and Other Eye Care) generated $2.109B of $61.160B total net revenues for the year ended 2025-12-31 (Form 10-K filed 2026-02-20).
Other Key Products
Other specialty/legacy pharmaceuticals (e.g., HCV antivirals, gastrointestinal, metabolic and other categories)
Revenue_share is derived from AbbVie FY2025 worldwide net revenues by product table: Other Key Products and residual other products generated $6.943B of $61.160B total net revenues for the year ended 2025-12-31 (Form 10-K filed 2026-02-20).
Evidence
no generic entry for any upadacitinib tablets is expected prior to April 2037 in the United States.
Direct company disclosure extending expected U.S. generic entry timing for Rinvoq (conditional on pediatric exclusivity).
composition of matter patents ... expected to expire in 2033.
The 10-K highlights Skyrizi and Rinvoq composition-of-matter patents as significant and expected to expire in 2033 (baseline before later settlement updates).
Net revenues for Skyrizi increased 24% for the three months and 26% for the six months ended June 30, 2026
At reported currency, H1 2026 Skyrizi and Rinvoq revenue was $9.988B and $4.644B; Humira fell 37.2% to $1.444B after biosimilar entry.
hold market-leading positions in the United States and in key markets around the world.
AbbVie directly describes the broader aesthetics portfolio as market-leading; Botox Cosmetic is approved in all major markets.
Net revenues for Botox Cosmetic increased 3% for the three months and 10% for the six months
H1 2026 Botox Cosmetic revenue rose 11.9% as reported to $1.396B, while Juvederm fell 3.0%, supporting a Botox-led rather than portfolio-wide brand advantage.
Risks & Indicators
Erosion risks
- Loss of exclusivity and biosimilar/generic entry (rapid net price and volume erosion)
- Patent challenges, adverse litigation outcomes, or settlements on less favorable terms
- Payer/formulary pressure and step-edits reducing realized net pricing
- U.S. drug pricing policy changes (rebates, negotiation frameworks, reimbursement changes)
- Competing mechanisms (new biologics, oral therapies, or novel modalities) shifting standards of care
- Consumer demand declines in recessions / discretionary spending weakness
Leading indicators
- Skyrizi and Rinvoq net revenue growth vs prior year
- Share trends in psoriasis/IBD/RA and other labeled indications
- Formulary positioning and rebate pressure in U.S. channels
- Patent litigation docket / settlement announcements for key assets
- Pipeline readouts and additional indication approvals
- Botox Cosmetic and Juvederm revenue trends and pricing/mix commentary
Research ABBV elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.